ReviewBritish journal of pharmacology2010
Refinement, reduction and replacement approaches to in vivo cardiovascular research.
Review in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Mapping the ethical and sustainable transition in toxicology: a bibliometric analysis and a review of new approach methodologies.Archives of toxicology · 2026Review
- A synthesis approach of mouse studies to identify genes and proteins in arterial thrombosis and bleeding.Blood · 2018Review
- Refinement of a mouse cardiovascular model: Development, application and dissemination.F1000Research · 2018Review
- Refinement of Mouse Protocols for the Study of Platelet Thromboembolic Responses In Vivo.Thrombosis and haemostasis · 2017Article
- Assessment of safety and efficacy of mesenchymal stromal cell therapy in preclinical models of acute myocardial infarction: a systematic review protocol.Systematic reviews · 2017Article
- Influence of inflammation and nitric oxide upon platelet aggregation following deposition of diesel exhaust particles in the airways.British journal of pharmacology · 2017Article
- The multifactorial role of the 3Rs in shifting the harm-benefit analysis in animal models of disease.European journal of pharmacology · 2015Article
- Animal Models in Cardiovascular Research: Hypertension and Atherosclerosis.BioMed research international · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
Abstract
In this review, the justification and benefits of refinement, reduction and replacement (3Rs) approaches to cardiovascular research are examined using the field of platelet biology and arterial thrombosis as an example. Arterial thrombosis is a platelet-driven condition and platelets are regulated by autologous signals, but also by external factors such as the vascular endothelium. In vitro assays using isolated platelets therefore poorly reflect in vivo platelet function and human disease. As a consequence, animal models, including mouse models, are frequently used. In particular, models of thromboembolic mortality have been successfully employed to determine the role of the vascular endothelium in regulating platelet function and thrombosis in vivo. Such models raise both scientific and ethical concerns and have recently been refined permitting the use of fewer mice at a lower severity level. These refinements have been scientifically beneficial in permitting analysis of the development and progression of thrombotic diseases and in improving our understanding of the role of the vascular endothelium in regulating platelet function and thrombosis. For many, the ultimate goal in 3Rs-driven science is replacement of animal models with non-animal alternatives; this is exemplified, in the platelet field, by the development of in vitro flow systems. The development of 3Rs approaches to cardiovascular research is shown to have led to improved scientific models. Further characterization and use of these models will likely contribute to increased understanding of thrombotic disease processes and facilitate drug development in the cardiovascular field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.